Can ondansetron cause cleft lip?

Can Ondansetron Cause Cleft Lip?

Ondansetron is associated with a very small absolute increase in orofacial cleft risk—approximately 3 additional cases per 10,000 births—but this minimal risk should not discourage its use when first-line antiemetics fail, as the harms of untreated severe nausea and vomiting in pregnancy outweigh this small teratogenic concern. 1

Absolute Risk in Context

The 2024 BJOG guideline provides the most clinically relevant framing of cleft risk:

• Background orofacial cleft risk: 11 cases per 10,000 births 1
• Risk with ondansetron exposure: 14 cases per 10,000 births 1
• Absolute risk increase: 3 additional clefts per 10,000 births 1

The relative risk is modest (adjusted RR 1.24,95% CI 1.03–1.48), derived from the largest cohort study of 1.8 million pregnancies with 88,467 first-trimester ondansetron exposures. 1, 2

Overall Malformation Risk: Reassuring Data

The most important finding is that ondansetron does NOT increase the overall rate of major congenital malformations. 1

• More than 97,000 first-trimester exposures across 12 studies (including meta-analyses) found no increase in overall malformation rates when compared to disease-matched or unexposed controls 1
• The largest single study (88,000 exposures) confirmed no association with overall malformations 1
• The UK Teratology Information Service systematic review explicitly concluded that "currently available data do not provide evidence that ondansetron use in the first trimester of pregnancy is associated with an increase in the overall malformation rate" 1

Cardiac Defects: Conflicting Evidence Resolved

The cardiac malformation concern has been addressed by higher-quality data:

• One smaller cohort reported increased cardiac defects (adjusted OR 1.43,95% CI 1.28–1.61) 1
• However, the larger and more robust study (88,467 exposures) found NO significant association after adjusting for confounders (adjusted RR 0.99,95% CI 0.93–1.06) 1, 2
• The FDA label acknowledges these inconsistent findings but notes that relative risks ranged from 0.97 to 1.62, with no confirmed association in the most rigorous studies 3

Critical Limitation: Confounding by Indication

A major methodological flaw in observational studies is comparing women with severe hyperemesis taking ondansetron to healthy women without nausea—this confounds the drug effect with disease severity. 1

When the comparison is done correctly:

• Studies comparing women with hyperemesis taking ondansetron versus women with hyperemesis taking OTHER antiemetics found no increased risk of major malformations 1
• Women with hyperemesis taking ondansetron had higher live-birth rates and lower pregnancy-termination rates compared to those not taking ondansetron 1

This suggests that treating severe nausea improves pregnancy outcomes overall, even if a tiny cleft risk exists. 4, 5

Treatment Algorithm Position

Ondansetron is recommended as second-line therapy after first-line agents (antihistamines, phenothiazines, or pyridoxine-doxylamine) fail. 1, 4, 5, 6

The stepwise approach is:

1. First-line: H1-antihistamines (promethazine, cyclizine), phenothiazines (prochlorperazine), or pyridoxine-doxylamine combinations 1, 6
2. Second-line: Ondansetron when first-line agents are ineffective 1, 4, 5
3. Alternative second-line: Metoclopramide (but requires slow IV administration ≥3 minutes to reduce extrapyramidal effects) 1, 4

Regulatory Divergence

• The European Medicines Authority (EMA) issued warnings to avoid ondansetron in the first trimester based on conflicting epidemiological data 1, 5
• The UK Medicines and Healthcare products Regulatory Agency (MHRA) did NOT issue a warning, reflecting divergent interpretation of the same evidence 1, 5
• The 2024 BJOG guideline explicitly states ondansetron "should not be discouraged if first-line antiemetics are ineffective" 1, 5

Counseling Framework

When discussing ondansetron with patients, address these points:

• Emphasize the small absolute increase: From 11 to 14 clefts per 10,000 births—a difference of 3 cases 1, 4
• Highlight the risks of untreated hyperemesis: Dehydration, electrolyte imbalance, weight loss, Wernicke encephalopathy, and higher pregnancy termination rates 4, 5
• Reassure about overall malformations: No increase in total birth defects or cardiac defects in the highest-quality studies 1, 4
• Discuss treatment alternatives: First-line agents should be tried first, but ondansetron remains a valid option when those fail 1, 6

Common Pitfalls to Avoid

• Do not withhold ondansetron based solely on the small cleft risk when severe nausea threatens maternal health or pregnancy continuation 1, 4
• Do not equate the modest relative risk (RR 1.24) with clinical significance without considering the low baseline rate 1
• Do not ignore confounding by indication when interpreting observational studies comparing sick women on ondansetron to healthy controls 1
• Do not assume all orofacial cleft associations are causal—two case-control studies reported conflicting results (OR 1.6 vs. 0.5 for cleft palate) 3, 7

FDA Label Perspective

The FDA label acknowledges:

• "Published epidemiological studies on the association between ondansetron use and major birth defects have reported inconsistent findings and have important methodological limitations that preclude conclusions about the safety of ondansetron use in pregnancy" 3
• One large Medicaid study showed increased oral cleft risk with oral ondansetron (RR 1.24,95% CI 1.03–1.48) but not with IV ondansetron (RR 0.95% CI 0.63–1.43), suggesting possible confounding 3
• Animal studies at 6–24 times the human dose showed no fetal harm 3